Drug Profile
Research programme: diabetes and obesity therapeutics - InMed Pharmaceuticals
Latest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Cannabis Technologies
- Developer InMed Pharmaceuticals
- Class Antihyperglycaemics; Cannabinoids; Obesity therapies
- Mechanism of Action Cannabinoid receptor modulators; Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 03 Nov 2021 InMed Pharmaceuticals has patent protection for manufacturing and formulation of cannabinoids
- 28 Jul 2018 No recent reports of development identified for research development in Diabetes-mellitus in Canada
- 28 Jul 2018 No recent reports of development identified for research development in Obesity in Canada